Meeting
2022 ASCO Annual Meeting
Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell lung cancer: A phase II study.
Authors
Jun Ni
Department of Pulmonary and Critical Care Medicine, Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
Jun Ni , Xiaotong Zhang , Ruili Pan , Hanping Wang , Xiaoyan Si , Xiaoxia Cui , Li Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04453930
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8573)
DOI
10.1200/JCO.2022.40.16_suppl.8573
Abstract #
8573
Poster Bd #
200
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2022 ASCO Annual Meeting
Preliminary safety and efficacy of camrelizumab plus nab-paclitaxel and carboplatin as frontline setting in extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
First Author: Shengxiang Ren
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
First Author: Huaying Wang
Poster
2021 ASCO Annual Meeting
Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.
First Author: Tiandong Kong